Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single dose Nexium [esomeprazole] 40mg qam vs lansoprazole 30mg bid for control of symptomatic GERD [gastro-oesophageal reflux] - a double-blind cross-over study

Next Previous
Search
Trial Profile

Single dose Nexium [esomeprazole] 40mg qam vs lansoprazole 30mg bid for control of symptomatic GERD [gastro-oesophageal reflux] - a double-blind cross-over study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esomeprazole (Primary) ; Lansoprazole
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use

Most Recent Events

  • 24 Feb 2009 Planned number of patients added to 50 as reported by ClinicalTrials.gov.
  • 24 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 24 Feb 2009 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top